DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Category Reports Biotech

Tickers reports and analysis

CAPR Capricor

CAPR Santa

Capricor Therapeutics [finance:Capricor Therapeutics, Inc.] is a clinical‑stage biotech focused on cell and exosome‑based therapeutics for rare diseases, with lead asset Deramiocel (CAP‑1002) targeting cardiomyopathy in Duchenne muscular dystrophy

SMMT Summit Therapeutics

Summit Therapeutics SMMT

ummit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical company focused on developing innovative oncology therapies. The primary pipeline is built around ivonescimab, a first-in-class bispecific antibody developed in partnership with Akeso Biopharma (China).

ADMA BIOLOGICS

ADMA

ADMA Biologics is a rare biotech company that combines clinical success with financial profitability. Unlike pre-revenue biotech plays, ADMA operates a functioning immunoglobulin (plasma-derived therapy) business generating $426.5M in FY2024 revenue (+65% YoY) with actual net income of $197.7M. The company is well-managed, debt-reducing, and positioned in a high-growth market ($53.5B global plasma therapy market projected by 2033).

OSCR Oscar Health

oscr-aca-catalyst-report-nov24-2025.html OSCR Breaking News | Oscar Health | Merlintrader ?? ?? OSCR BREAKING CATALYST ACA SUBSIDY EXTENSION November 24, 2025 | Political Healthcare Policy Breakthrough OSCR CATALYST ACUTO ESTENSIONE SUSSIDI ACA 24 Novembre 2025 | Breakthrough Politica Healthcare Executive Summary…

ENLV Enlivex Therapeutics 

ENLV

Enlivex Therapeutics [finance:Enlivex Therapeutics Ltd.] announced two simultaneous catalysts on November 23-24, 2025, triggering a 74% intraday spike to $1.59: (1) positive 6-month topline data from the Allocetra Phase IIa trial demonstrating durable pain reduction, and (2) a $212M PIPE financing at $1.00/share closing November 25. The clinical data supports Phase IIb progression, but the financing creates massive shareholder dilution (~99%) and introduces governance/crypto risks requiring careful assessment.

RGNX REGENXBIO 

Currently at channel support , technically a good entry point . REGENXBIO Inc. (RGNX) is facing a landmark FDA decision on February 8, 2026 regarding approval of RGX-121 (clemidsogene lanparvovec), a one-shot AAV gene therapy for MPS II (Hunter Syndrome).